In the intrinsic pathway of apoptosis, cell-damaging signals promote the release of cytochrome c from mitochondria, triggering activation of the Apaf-1 and caspase-9 apoptosome. The ubiquitin E3 ligase MDM2 decreases the stability of the proapoptotic factor p53. We show that it also coordinated apoptotic events in a p53-independent manner by ubiquitylating the apoptosome activator CAS and the ubiquitin E3 ligase HUWE1. HUWE1 ubiquitylates the antiapoptotic factor Mcl-1, and we found that HUWE1 also ubiquitylated PP5 (protein phosphatase 5), which indirectly inhibited apoptosome activation. Breast cancers that are positive for the tyrosine receptor kinase HER2 (human epidermal growth factor receptor 2) tend to be highly aggressive. In HER2-positive breast cancer cells treated with the HER2 tyrosine kinase inhibitor lapatinib, MDM2 was degraded and HUWE1 was stabilized. In contrast, in breast cancer cells that acquired 
INTRODUCTION
Mutation of the tumor suppressor p53 in ~50% of human tumors promotes both unrestrained cell proliferation and a failure of cells to die appropriately by apoptosis (1, 2) . MDM2 is a key p53 inhibitor and prevents transcription of p53 target genes and induces p53 polyubiquitylation and degradation (3) (4) (5) (6) (7) . In this regard, MDM2 has been viewed as an indirect, p53-dependent apoptotic regulator.
In a subset of cancers, tumorigenesis is driven by aberrantly activated tyrosine kinases that promote prosurvival and antiapoptotic signaling (8) (9) (10) . In these tumors, targeted kinase inhibition triggers apoptosis and tumor regression. However, development of acquired therapeutic resistance has limited the clinical efficacy of this important class of targeted cancer drugs. Therapeutic resistance can result from mutations in the tyrosine kinase itself (for example, imatinib-resistance stemming from mutation of Bcr-Abl in chronic myeloid leukemias), but this is not always the case (11, 12) . Under these circumstances, dissection of signal transduction pathways in resistant cells may reveal novel interactions among signaling molecules.
Overexpression or amplification of the HER2 (human epidermal growth factor receptor 2) receptor tyrosine kinase in 20 to 30% of breast cancers is associated with poor clinical outcomes (13) . Several HER2-targeted therapeutics have been approved or are in clinical trials, including trastuzumab (trade name Herceptin), a monoclonal antibody directed against the extracellular domain of HER2, and lapatinib (trade name Tykerb), a small molecule that reversibly inhibits the kinase activities of HER2 and EGFR (epidermal growth factor receptor) (14, 15) . Conventionally, a breast cancer patient undergoes lapatinib treatment after the development of therapeutic resistance to trastuzumab. However, the antitumor effects of lapatinib monotherapy are generally short-lived, with cancer cells inevitably developing resistance to this drug over time (16) .
Because mutations in HER2 itself are not typically seen in acquired lapatinib resistance, alternative mechanisms underlying acquired lapatinib resistance have been evaluated (15, (17) (18) (19) (20) (21) (22) . Several studies have identified apoptotic inhibitors that show increased abundance in lapatinib-resistant cells, including X-linked inhibitor of apoptosis protein (XIAP) (18) and Mcl-1, an antiapoptotic Bcl-2 family member [seen in lapatinib-resistant colon cancer cells (19) ]. It has been recently demonstrated that the simultaneous inhibition of the Bcl-2 family proteins Bcl-2, Bcl-xL, and Mcl-1 can synergize with lapatinib (23) . Nevertheless, the molecular basis of acquired resistance remains to be fully elucidated.
In seeking to understand the molecular basis of lapatinib resistance, we undertook a systematic comparison of apoptotic signaling pathways in isotype-matched lapatinibsensitive and lapatinib-resistant HER2 + breast cancer cells. We identified multiple antiapoptotic alterations both upstream and downstream of mitochondria in resistant cells. These studies revealed an unexpected signaling network in which the ubiquitin E3 ligase MDM2 ubiquitylated another E3 ligase, HUWE1, thereby increasing the abundance of its substrates, Mcl-1 and protein phosphatase 5 (PP5), an indirect inhibitor of the apoptosome. Thus, HUWE1 transmits a signal from MDM2 to control apoptotic events both upstream and downstream of mitochondria. These MDM2-dependent pathways were subverted in lapatinib-resistant cells, and regardless of cellular p53 status, inhibition of MDM2 rectified apoptotic defects, thereby overcoming drug resistance.
RESULTS

Mcl-1 stabilization in lapatinib-resistant breast cancer cells
To analyze the molecular mechanisms underlying lapatinib resistance, we derived four independent lapatinib-resistant HER2-positive breast cancer cell lines by continuous culture of BT474, SKBR3, SUM190, and AU565 cells in the presence of clinically relevant concentrations of lapatinib (20) . Regardless of estrogen receptor, progesterone receptor, or p53 status ( fig. S1 and table S1 ), all four parental sensitive cell lines died from apoptosis in response to lapatinib, whereas all four resistant lines (hereinafter referred to as rBT474, rSKBR3, rSUM190, and rAU565) did not (Fig. 1A and fig. S2 ). As previously reported (20) , lapatinib inhibited the tyrosine autophosphorylation of HER2 even in resistant cells (Fig. 1B) . Furthermore, phosphorylation of both Akt and extracellular signal-regulated kinase 1/2 (ERK1/2), two primary downstream effectors in HER2-positive breast cancer, was also attenuated in sensitive and resistant cells treated with lapatinib (Fig. 1, C and D) . Note that we did not detect a consistent increase in the kinase activity of SRC ( fig. S3 ), which has been implicated in acquired resistance to trastuzumab or lapatinib in HER2-positive breast cancer (21, 24) , nor did the SRC inhibitor dasatinib affect MDM2 protein abundance or apoptotic resistance in lapatinib-resistant cells ( fig. S4 ).
Because lapatinib promotes tumor regression, at least in part, by inducing apoptosis, we speculated that apoptotic signaling might be altered in resistant cells. Indeed, lapatinib induced mitochondrial cytochrome c release in parental BT474 cells, but not rBT474 cells ( fig. S5 ), suggesting that pro-and antiapoptotic Bcl-2 family proteins that govern the mitochondrial outer membrane permeability might be modulated in the lapatinib-treated resistant cells. Although there did not appear to be substantial differences in the abundance of the Bcl-2 family member Bim (Fig. 1E ) between sensitive and resistant cells, as reported for colon cancer cells (19) , the abundance of the antiapoptotic Bcl-2 member Mcl-1 was increased in the resistant breast cancer cells treated with lapatinib ( Fig. 1E and fig. S6 ); in the sensitive cells, Mcl-1 abundance decreased upon treatment with lapatinib, whereas Mcl-1 abundance increased in the resistant cells maintained in the presence of lapatinib ( Fig.  1E and fig. S6 ). 35 S-labeled Mcl-1 was rapidly degraded in cell-free lysates prepared from sensitive cells, but was markedly delayed in those prepared from resistant cells, indicating that the observed differences in Mcl-1 abundance stemmed from differences in Mcl-1 stability (Fig. 1F and  fig. S7 ). Although the Mcl-1 protein half-life was prolonged in resistant cell lysates, this was particularly prominent in lysates from cells treated with lapatinib (for example, lapatinibtreated rBT474 cells) (Fig. 1G) . Addition of the deubiquitylase inhibitor ubiquitin aldehyde to the lysates did not prevent the failure to degrade 35 S-labeled Mcl-1 in resistant cells ( fig.  S8 ), suggesting that Mcl-1 stabilization might be secondary to a defect in Mcl-1 ubiquitylation, rather than enhanced deubiquitylation. To examine Mcl-1 ubiquitylation directly, we co-transfected FLAG-tagged Mcl-1 together with hemagglutinin (HA)-tagged ubiquitin and examined the ubiquitylation of immunoprecipitated Mcl-1. In the absence of lapatinib, Mcl-1 protein was equally ubiquitylated in SKBR3 and rSKBR3 cells (Fig. 1H) . Lapatinib treatment enhanced Mcl-1 ubiquitylation in SKBR3 cells but diminished Mcl-1 ubiquitylation in rSKBR3 cells (Fig. 1H) , suggesting that the increased abundance of Mcl-1 protein in the lapatinib-resistant cells might result from a lapatinib-dependent defect in the Mcl-1 ubiquitylation machinery.
Incorrect apoptosome assembly in lapatinib-resistant cells
In analyzing the mechanism of lapatinib resistance, we noted that the resistant cells failed to activate caspases when purified cytochrome c was added directly to lysates, whereas cytochrome c induced robust caspase activation in parental cells, although the abundance of Apaf-1, caspase-9, and caspase-3 was similar in resistant and sensitive cells ( Fig. 2A and  fig. S9 ). As we observed for Mcl-1 protein stability, the failure of cytochrome c to induce caspase activation in lapatinib-resistant cells was lapatinib-dependent. Caspase activation did not occur in lysates from resistant cells cultured in the presence of lapatinib, a defect that was rescued by removing lapatinib from the culture medium (Fig. 2, A and B) .
PP5 stabilization in lapatinib-resistant breast cancer cells
Recruitment of caspase-9 to the apoptosome is blocked by HSP90 binding to the CARD (caspase recruitment domain) domain of Apaf-1. In leukemia cells, decreased phosphorylation of HSP90 at residues Ser 226 and Ser 255 leads to a stronger interaction between Apaf-1 and HSP90 (25) . Phosphorylation of HSP90 at both Ser 226 and Ser 255 was also markedly decreased in lapatinib-treated resistant cells compared to sensitive cells (Fig. 2, C, D , and E).
Because lapatinib did not prevent the phosphorylation of HSP90 in parental BT474 cells (Fig. 2C) , lapatinib was unlikely to inhibit an HSP90 -directed kinase [such as casein kinase 2 (CK2) (26) (fig. S10) ], suggesting that an HSP90 -directed phosphatase might be modulated in response to lapatinib. PP5 has been reported to control the phosphorylation status of HSP90 (27) . Therefore, we hypothesized that the decreased phosphorylation of HSP90 in lapatinib-resistant cells might result from increased PP5 activity. Indeed, lapatinib treatment triggered a gradual decrease in PP5 abundance in sensitive parental cells, but not in resistant cells (Fig. 2F and fig. S11 ). Moreover, the protein half-life of PP5 was longer in resistant than in the parental cells (Fig. 2G) . Accordingly, the ubiquitylation of PP5 was greater in sensitive than in resistant cells (Fig. 2H ).
The role of the ubiquitin E3 ligase HUWE1 in the degradation of both Mcl-1 and PP5 PP5 stabilization could result from a defect in an E3 ligase activity responsible for PP5 ubiquitylation in lapatinib-resistant cells. Hence, we sought to identify a PP5-directed E3 ligase through chromatographic purification. Cytosolic lysates prepared from SKBR3 cells were fractionated on a Q Sepharose column, and ubiquitylation of 35 S-labeled PP5 by each fraction [supplemented with E1, E2, ATP (adenosine 5 -triphosphate), and ubiquitin] was analyzed by SDS-polyacrylamide gel electrophoresis. Most of the PP5-ubiquitylating activities were eluted with 500 mM NaCl ( fig. S12 ). Because Mcl-1 stability changed in response to lapatinib, we speculated that an Mcl-1-directed E3 ubiquitin ligase might also regulate PP5 stability. Indeed, immunoblotting of Q Sepharose fractions revealed that HUWE1 (also known as Mule, ARF-BP1, and HectH9), a HECT domain E3 ligase that targets Mcl-1 for degradation (28) , was also eluted with 500 mM NaCl, corresponding to the fraction with PP5-ubiquitylating activity ( fig. S12 ).
In agreement with these observations, we found that HA-HUWE1 co-immunoprecipitated with endogenous PP5 (Fig. 3A) . Moreover, knockdown of HUWE1 by small interfering RNA (siRNA) increased the abundance of both PP5 and Mcl-1 in BT474 cells (Fig. 3B) . Conversely, overexpression of HA-HUWE1, but not catalytically inactive HA-HUWE1(C/ S), reduced PP5 and Mcl-1 protein abundance ( Fig. 3C and fig. S13 ). In the presence of both E1 and E2, wild-type recombinant HUWE1 protein, but not HUWE1(C/S), ubiquitylated recombinant PP5 in vitro (Fig. 3D) . In BT474 cells, binding of PP5 to HUWE1 markedly increased after lapatinib treatment (Fig. 3E ). In contrast, association of PP5 with HUWE1 was undetectable in rBT474 cells regardless of lapatinib treatment (Fig. 3E) . Together, these results suggested that HUWE1 is a bona fide E3 ligase for PP5.
Decreased abundance of CAS in lapatinib-resistant cells
Decreased phosphorylation of HSP90 downstream of PP5 stabilization might explain apoptosome inhibition in the lapatinib-treated resistant cells, but when we resolved cell lysates by gel filtration, we saw not only a failure to recruit caspase-9 to Apaf-1 (which could be explained if HSP90 blocked caspase-9 recruitment) but also a failure of the majority of Apaf-1 to oligomerize (Fig. 3F) . Moreover, upon addition of cytochrome c to resistant cell lysates, we detected a small fraction of Apaf-1 and caspase-9 in large (1000 to 1400 kD) fractions (Fig. 3F , shown by asterisks), which has been previously described as incorrectly assembled inactive complexes (29) .
Without nucleotide exchange, cytochrome c induces Apaf-1 to form non-functional aggregates (29) . Accordingly, we examined the abundance of PHAP1, HSP70, and CAS (also known as CSE1L or Exportin-2), essential components of the nucleotide exchange factor required for loading Apaf-1 with dATP (29) . We found that CAS protein abundance was decreased in resistant cells compared with parental cells, most notably in the presence of lapatinib ( Fig. 4A and fig. S14 ). CAS protein abundance declined over time after the addition of lapatinib to resistant cells, but lapatinib removal restored the abundance of CAS to levels comparable to the parental cells (Fig. 4 , A and B). Treatment of parental cells with lapatinib did not affect CAS protein abundance (Fig. 4A ). CAS protein was stabilized in sensitive cells, but destabilized in lapatinib-treated resistant cells (Fig. 4C) . Accordingly, ubiquitylation of CAS was nearly undetectable in sensitive cells even in the presence of MG132, whereas ubiquitylated species of CAS were readily detected in resistant cells and more prominent in the presence of lapatinib ( Fig. 4D and fig. S15 ). These data suggest that decreased CAS abundance in lapatinib-resistant cells results from augmented CAS protein ubiquitylation.
To determine the mode of CAS degradation, we analyzed the CAS protein sequence and identified a potential binding motif for the RING finger ubiquitin ligase MDM2 (30, 31) (fig. S16). CAS interacts with p53 (32); however, MDM2 coimmunoprecipitated with CAS in BT474 and p53-null H1299 cells (Fig. 4 , E and F). When Trp 127 , a conserved residue in the MDM2 binding motif, was replaced with Ala, binding of CAS to MDM2 was diminished (Fig. 4E) . Moreover, when expressed in H1299 cells lacking p53, ubiquitylation of CAS W127A was suppressed compared with that of wild-type CAS (Fig. 4G) . Furthermore, transient overexpression of MDM2 decreased the abundance of wild-type CAS, but not that of the F123A mutant in which the conserved Phe 123 in the MDM2 binding motif was replaced with Ala ( Fig. 4H) . Together, these results indicate that CAS is an MDM2 target. In BT474 cells, the CAS-MDM2 interaction decreased in the presence of lapatinib, whereas binding was enhanced in rBT474 cells under the same conditions (Fig. 4F) , consistent with the idea that augmented ubiquitylation and subsequent degradation of CAS protein in lapatinib-resistant cells are mediated by MDM2.
Identification of MDM2 as a HUWE1-directed E3 ligase
High HUWE1 and low MDM2 activities in sensitive cells resulted in reduced abundance of Mcl-1 and PP5 and sustained abundance of CAS, respectively, rendering the sensitive cells prone to apoptosis. In parental cells, HUWE1 protein abundance remained stable in the presence of lapatinib, whereas MDM2 rapidly decreased (Fig. 5A and fig. S17 ). Conversely, when resistant cells were treated with lapatinib, HUWE1 abundance decreased, whereas MDM2 abundance was maintained (Fig. 5A and fig. S17 ). Reduction of HUWE1 in resistant cells appeared to be due to lapatinib-induced protein degradation. In the absence of lapatinib, HUWE1 was stable in both BT474 and rBT474 cells. However, in lapatinibtreated rBT474 cells, HUWE1 protein half-life became considerably shorter, compared to that in BT474 cells (Fig. 5B) . Although both HUWE1 and MDM2 are p53-targeting E3 ligases (5-7, 33) (and MDM2 abundance can also be modulated in a feedback loop by p53-induced transcription), mutant p53 is present in three of the four cell lines (BT474, SKBR3, and SUM190) (table S1 and fig. S1 ), suggesting that the observed changes in HUWE1 and MDM2 protein abundance are independent of the transcriptional activity of p53.
Through protein sequence analysis, we determined that HUWE1 contained a putative MDM2 binding motif at residues 1198 to 1205 (fig. S18) ; the interaction of these two E3 ligases was confirmed by immunoprecipitation of endogenous proteins ( fig. S19 ). The Nterminal portion of the HUWE1 protein (amino acids 1 to 2474) as well as the full-length protein interacted with MDM2 (Fig. 3A) . Moreover, replacement of the conserved Trp 1202 with Ala (HUWE1 W1202A ) reduced binding between the two proteins (Fig. 5C) . The HUWE1-MDM2 interaction was evident not only in BT474 cells but also in H1299 cells, again indicating that their binding is neither specific for breast cancer cells nor mediated by p53 (Figs. 3A and 5C and fig. S19 ). To examine the binding affinity between HUWE1 and MDM2, we performed fluorescence polarization-based competitive binding assays using recombinant MDM2 protein and modified p53 peptide labeled with FAM as a fluorescent probe (34) . The HUWE1 peptide competitively inhibited binding of the fluorescent probe to MDM2 with a K i (inhibition constant) value of 1.5 M and was a threefold more potent inhibitor of probe binding than the p53 peptide (amino acids 13 to 29, which constitutes the MDM2 binding motif) (Fig. 5D ).
To determine whether MDM2 is a HUWE1-directed E3 ligase, we overexpressed MDM2 in H1299 cells. MDM2 expression reduced HUWE1 protein abundance in a dose-dependent manner (Fig. 5E ). In contrast, siRNA knockdown of MDM2 increased HUWE1 protein abundance (Fig. 5F ). Using a truncated mutant of HUWE1 (HUWE1 ) to allow visualization of an electrophoretic mobility shift, we confirmed that, in the presence of both E1 and E2, MDM2 could ubiquitylate HUWE1 in vitro (Fig. 5G) . Last, we demonstrated that lapatinib treatment triggered degradation of HUWE1 in resistant cells transfected with control siRNA, but when these cells were transfected with MDM2 siRNA, HUWE1 stability was markedly increased, even in the presence of lapatinib (Fig. 5H) . Together, these results are consistent with MDM2 acting as a HUWE1-directed ligase.
Reversal of lapatinib resistance by inhibition of MDM2
Our findings raised the interesting possibility that the changes in Mcl-1, PP5, and CAS in lapatinib-resistant cells could all be traced to high MDM2 activity in the resistant cells. Accordingly, when resistant cells were co-treated with lapatinib, MDM2 knockdown induced significant apoptotic cell death (Fig. 6A) . To evaluate this further, we implanted xenografts of rBT474 cells stably expressing control or MDM2 short hairpin RNAs (shRNAs) into the mammary fat pads of female nude mice (Fig. 6B) . Without lapatinib treatment, tumors developed similarly for all tumors. Oral lapatinib administration induced regression of xenografted tumors expressing MDM2 shRNAs, whereas control tumors continued to grow (Fig. 6B) . Moreover, by the end of the treatment period, 6 of 10 mice in the MDM2 knockdown group had tumors smaller than 50 mm 3 .
A hydrophobic pocket in the N terminus of MDM2 binds to the trans-activation domain of p53 (30) . If MDM2 bound HUWE1 in the same fashion as suggested by the fluorescence polarization-based assays (Fig. 5D) , the MDM2 antagonist Nutlin-3a, which disrupts the p53-MDM2 complex, might also be expected to interfere with HUWE1-MDM2 binding (35) . To exclude the possibility that any effects of Nutlin-3a might be mediated by the p53-MDM2 interaction, we used p53-null H1299 cells. Catalytically inactive HUWE1
[HUWE1(C/S)] bound to endogenous MDM2, and this interaction was reduced by Nutlin-3a (Fig. 6C) . Moreover, Nutlin-3a also prevented lapatinib-induced degradation of HUWE1 (Fig. 6D and fig. S20 ), suggesting that Nutlin-3a stabilizes HUWE1 by disrupting HUWE1-MDM2 binding. Consequently, Nutlin-3a also suppressed lapatinib-induced up-regulation of Mcl-1 and PP5 (Fig. 6D and fig. S20 ). CAS degradation was also inhibited by Nutlin-3a (Fig. 6D and fig. S20 ).
To examine the effect of Nutlin-3a in vivo, mice bearing BT474 or rBT474 xenografts were randomly assigned to vehicle, lapatinib, Nutlin-3 (a racemic mixture of the enantiomers Nutlin-3a and Nutlin-3b), or lapatinib and Nutlin-3. Lapatinib alone or a combination of lapatinib and Nutlin-3 significantly suppressed growth of BT474-derived tumors, whereas Nutlin-3 alone only modestly inhibited tumor growth (Fig. 6E) . Neither lapatinib nor Nutlin-3 inhibited rBT474-derived tumor growth as a single agent (Fig. 6E) . However, combination treatment of lapatinib and Nutlin-3 significantly suppressed tumor growth, resulting in ~50% reduction in tumor volume (Fig. 6E) . These experiments were repeated using p53-positive AU565 and rAU565 cells. Lapatinib substantially inhibited the growth of tumors derived from AU565 cells, but not those derived from rAU565 cells (fig. S21 ). Nutlin-3 treatment alone moderately inhibited the growth of tumors derived from these p53-positive cells, but combined lapatinib and Nutlin-3 treatment reduced tumor volume bỹ 50% by the end of the evaluation period ( fig. S21 ). Tissue culture experiments conducted in parallel with all four sensitive and resistant cell line pairs using the MDM2 antagonist MI-219 (34) suggest that similar effects are likely to be obtained with other MDM2 inhibitors ( fig. S2) . Moreover, the ability of the MDM2 inhibitors to resensitize resistant cells to lapatinib was not compromised by RNA interference (RNAi)-mediated knockdown of p53 in rAU565 cells (Fig. 6F) . Together, these results demonstrate that regardless of p53 status, an MDM2 inhibitor such as Nutlin-3a or MI-219 can reverse lapatinib resistance, potentially by stabilizing CAS and HUWE1, thereby promoting loss of PP5 and Mcl-1 (Fig.  6G ).
DISCUSSION
Here, we have demonstrated that multiple changes in the abundance of apoptotic regulators, both upstream and downstream of mitochondrial cytochrome c release, cause resistance to lapatinib. Furthermore, these changes could be attributed to a previously unsuspected network of MDM2 (and HUWE1) substrates that does not include p53. Failure to degrade MDM2 in response to lapatinib in all four independently derived lapatinib-resistant cell lines was the key factor in increasing the abundance of components of the antiapoptotic machinery in these cells (Fig. 6G) .
We identified changes in mitochondrial cytochrome c release after lapatinib treatment, but we have also found that the apoptosome is refractory to cytochrome c-induced activation in the resistant cells. There is some debate as to the importance of apoptosome inhibition in cancers that already have a block to mitochondrial cytochrome c release. However, we postulate that the block is more profound when several loci in the apoptotic pathway are affected: Even if small amounts of cytochrome c were released in response to lapatinib in the resistant cells, efficient caspase activation would be inhibited at the level of the apoptosome. Because the abundance of both PP5 and Mcl-1 is controlled by HUWE1, apoptotic inhibition both upstream and downstream of the mitochondria could be controlled coordinately.
We also determined that the abundance of CAS was decreased through MDM2-mediated ubiquitylation. Knockdown of CAS renders breast cancer cells resistant to apoptosis (36) . CAS also binds to a subset of p53 target genes to regulate p53-mediated gene expression (32) . In this regard, our results raise the interesting possibility that, in addition to ubiquitylation of p53, MDM2 might also modulate the p53 signaling pathway by targeting CAS for degradation.
Notably, high MDM2 activity promotes not only degradation of CAS protein but also a decrease in HUWE1 abundance (and thus increased stability of its substrates). Although several proteins have been identified as substrates of HUWE1, such as Cdc6, p53, and NMyc/c-Myc, little is known about the regulation of this E3 ligase (28, 33, (37) (38) (39) . It should be noted that MDM2 substrates in addition to HUWE1 and CAS may also contribute to lapatinib resistance. For example, MDM2 enhances IRES (internal ribosome entry site)-mediated translation of XIAP (40) . In this regard, it is noteworthy that increased IRESmediated XIAP translation has been implicated in inflammatory breast cancer cells with acquired resistance to lapatinib (18) .
The basis for the difference in MDM2 abundance in resistant and sensitive cells is not clear. This could be secondary to differences in protein stability or in transcription between resistant and sensitive cells. It is possible that a mutation, modification, or unidentified binding partner renders MDM2 unable to auto-ubiquitylate, but still able to ubiquitylate substrates in trans. Alternatively, failure to degrade MDM2 in the resistant cells could result from a mutation in MDM2 itself, rendering it insensitive to degradative signals triggered by lapatinib in sensitive cells. Answering these questions will provide a stepping stone from MDM2 to the relevant signaling factor(s) primarily responsible for the lapatinib resistance while revealing additional nodes in the MDM2 and HUWE1 regulatory network.
MATERIALS AND METHODS
Cell culture
BT474, SKBR3, and AU565 cells were obtained from the American Type Culture Collection (ATCC). SUM190 cells were obtained from Asterand Inc. All cell lines were cultured in RPMI medium containing 10% fetal bovine serum (FBS). Lapatinib-resistant cells (rBT474, rSKBR3, rAU565, and rSUM190) were established as previously described (20) . Lapatinib-resistant cells were maintained in the presence of 1 M lapatinib unless otherwise stated. However, the resistant cells were cultured in lapatinib-free medium for 7 days before the treatment with lapatinib. H1299 cells (from ATCC) were maintained in Dulbecco's modified Eagle's medium with 10% FBS.
Reagents and antibodies
Lapatinib and dasatinib were purchased from LC Laboratories. MG132 and z-VAD were purchased from Enzo Life Sciences. E1, E2, ubiquitin, and ubiquitin aldehyde were purchased from Boston Biochem. Nutlin-3a and racemate Nutlin-3 were synthesized and purified at the Duke Small Molecule Synthesis Facility. Nutlin-3a and Nutlin-3 were also purchased from Cayman Chemical. Cycloheximide and purified cytochrome c were purchased from Sigma. 
Plasmids
HA-HUWE1 constructs in pCMV (porcine cytomegalovirus; wild type, C4341S mutant, and amino acids 2473 to 4374 mutant) were gifts from K. Helin (University of Copenhagen). HUWE1 in pENTR was a gift from J. G. Cook (University of North Carolina, Chapel Hill, NC). HUWE1 in pENTR was recombined with the destination vector pDEST10 (Invitrogen) for production of His-tagged protein. FLAG-PP5 in pcDNA3 and FLAG-CAS in p3XFLAG-CMV10 were gifts from X.-F. Wang (Duke University) and C. Prives (Columbia University), respectively. CAS was also cloned into pENTR and subsequently into pDEST10 for baculoviral protein expression. PP5 was cloned into pGEX-KG for production of glutathione S-transferase (GST) fusion protein. Mcl-1 with the N-terminal FLAG tag was generated from human Mcl-1 (a gift from J. Rathmell, Duke University) and cloned into pcDNA3. The plasmids encoding GST-MDM2, GST-MDM2 C464A , and HA-tagged ubiquitin were obtained from Addgene (Addgene plasmids 11492, 11493, and 17608) (41, 42) . MDM2 was also cloned into pcDNA3 with an N-terminal FLAG tag. All point mutations (HA-HUWE1 1-2474 , HA-HUWE1 W1202A , His-HUWE1 C4341S , FLAG-CAS W127A , FLAG-CAS F123A ) were generated with the QuikChange mutagenesis kit (Stratagene).
RNA interference
Transient siRNA transfections were performed with Lipofectamine RNAiMAX (Invitrogen) according to the manufacturer's instructions. MDM2-specific siRNA (sense: 5 -CACCUCACAGAUUCCAGCUUCGGAA-3 ) and its scrambled siRNA control (sense: 5 -CACACACUUAGGACCCUUCGU-CGAA-3 ) were designed and synthesized by Invitrogen. siRNA oligos targeting HUWE1 or GFP were previously described (37).
For stable knockdown of MDM2, an shRNA construct in the lentiviral vector pLKO.1-puro (shMDM2 #1) was purchased from Open Biosystems (sense: 5 -GATTCCAGAGAGTCATGTGTT-3 ). Additional MDM2 shRNA construct (shMDM2 #2; sense: 5 -TTGAAGTTATTAAAGTCTGTT-3 ) and control shRNA construct (sense: 5 -CTGTGCTGTAGGTGAAACTGT-3 ) were also created in the vector pLKO.1-puro according to Addgene's pLKO.1 protocol (http://www.addgene.org/plko). Stable knockdown of p53 was performed with the vector shp53-pLKO.1-puro (Addgene plasmid 19119) (43) .
Mouse xenograft experiments
Six-week-old female nude mice were purchased from the National Cancer Institute (NCI) Frederick National Laboratory. Xenograft tumors were produced by injection into the mammary fat pad with cells (10 × 10 6 ). Tumor volumes were calculated every 3 to 4 days by caliper measurements of the short (a) and long (b) tumor diameters (volume = a × 2 × b/ 2). Lapatinib and Nutlin-3 were formulated in vehicle (water with 0.5% hydroxypropyl methylcellulose and 0.1% Tween). Mice were dosed orally with vehicle alone, lapatinib (100 mg/kg), Nutlin-3 (100 mg/kg), or combination of both twice daily by gavage.
Immunoprecipitation
Cells were transiently transfected with the indicated plasmid by FuGene 6 (Roche) according to the manufacturer's instructions. Cells were harvested and lysed with coimmunoprecipitation buffer [10 mM Hepes (pH 7.4), 150 mM KCl, 0.5% NP-40, 1 mM phenylmethylsulfonyl fluoride, leupeptin (5 g/ml), and aprotinin (5 g/ml)]. Cell lysate was incubated with anti-FLAG M2 agarose (Sigma) or anti-HA affinity matrix (Roche) at 4°C for 2 to 3 hours. The bead pellet was washed three times with coimmunoprecipitation buffer and then incubated with SDS sample buffer.
Apoptosis assays
Cell lysates for apoptotic assays were prepared as described previously with buffer A [20 mM Hepes (pH 7.4), 10 mM KCl, 1.5 mM MgCl2, 1 mM EDTA, 1 mM EGTA, 1 mM dithiothreitol (DTT), 1 mM phenylmethylsulfonyl fluoride, leupeptin (5 g/ml), and aprotinin (5 g/ml)] (25). Cell lysate (10 g/ l) was incubated in the presence or absence of 1 mM dATP and various concentrations of cytochrome c at 37°C for 30 min and subjected to gel filtration, caspase assays, or Western blotting.
Gel filtration was performed as previously described (25) . After incubation with cytochrome c, the cell lysate (in a volume of 250 l) was loaded onto a Superdex 200 column at a flow rate of 0.3 ml/min.
Colorimetric caspase assays were performed by incubating cell lysate (3 l) in 90 l of DEVDase buffer [50 mM Hepes (pH 7.5), 100 mM NaCl, 0.1% CHAPS, 10 mM DTT, 1 mM EDTA, 10% glycerol] containing the peptide substrate, Ac-DEVD-pNA (200 mM final concentration; BIOMOL Research Laboratories). Reactions were incubated at 37°C for 30 min. Absorbance of the colorimetric product was measured at 405 nm with a Bio-Rad microplate reader.
In vitro ubiquitylation assays
Recombinant human PP5 and MDM2 proteins were bacterially expressed with a GST tag. After purification by glutathione Sepharose 4B (GE Healthcare), the GST tag was cleaved off by thrombin. Recombinant human wild-type HUWE1, the C4341S mutant (HUWE1 C/ S), and HUWE1 were expressed in the baculovirus system and purified from Sf9 cells.
For in vitro ubiquitylation assays, 100 ng of purified recombinant PP5 or HUWE1 1-2474 was incubated with 10 ng of E1, 100 ng of E2 (UbcH5b or UbcH7), 100 g of ubiquitin, and 0.5 g of a purified E3 enzyme (HUWE1 wild type, HUWE1 C/S, or MDM2) in 40 l of reaction buffer [50 mM tris (pH 7.5), 5 mM MgCl 2 , 2 mM ATP, 2 mM DTT]. After incubation at 30°C for 3 hours, the reaction was terminated by the addition of SDS sample buffer.
Fluorescence polarization binding assays
The binding affinities of HUWE1 and p53 peptides to MDM2 protein were determined by a quantitative fluorescence polarization-based competitive binding assay, with a recombinant human His-tagged MDM2 protein (residues 1 to 118) and a FAM-tagged modified p53 peptide as the fluorescent probe (34) . The following peptide sequences were tested: p53, Ac-LSQETFSDLWKLLPENNVL-NH 2 ; HUWE1, Ac-DGTGEFLDAWLMLVEKMVN-NH 2 .
Statistics
The statistical analysis was carried out with GraphPad Prism software version 4.0c and R software version 2.15.2. For the densitometric analyses of the immunoblots, significance was computed with a paired, two-tailed t test on Western blot intensities after normalizing to the relevant control (CAS, HUWE1, or actin) and after log transforming to correct for skewness in the distribution.
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Refer to Web version on PubMed Central for supplementary material. Densitometric analysis of the abundance of CAS normalized to that of actin from four independent experiments (means ± SEM) is shown (bottom). CAS abundance at time 0 was set at 100%. (C) BT474 and rBT474 cells expressing FLAG-tagged CAS were treatedwith cycloheximide(CHX)andlapatinibfortheindicated times and immunoblotted for FLAG and actin (top). Densitometric analysis of the abundance of FLAG-CAS normalized to that of actin from four independent experiments (means ± SEM) is shown (bottom). FLAG-CAS abundance at time 0 in each cell line was set at 100%. (D) BT474 and rBT474 expressing FLAG-CAS and HA-Ub were treated with lapatinib and z-VAD and harvested after MG132 treatment. FLAG-CAS immunoprecipitates were immunoblotted for HA to analyze ubiquitylation of CAS. n = 2 independent experiments. (E) H1299 cells were transfected with empty vector, FLAG-CAS WT, or FLAG-CAS W127A . Immunoprecipitates of the FLAG-tagged proteins were immunoblotted for MDM2. Densitometric analysis of the abundance of immunoprecipitated MDM2 normalized to that of FLAG-CAS WT or FLAG-CAS W127A from four independent experiments is shown (means ± SEM). The amount of MDM2 bound to FLAG-CAS WT was set at 100% (*P < 0.05 by paired, two-tailed t test). (F) BT474 and rBT474 cells expressing FLAG-CAS were treated with lapatinib and z-VAD and harvested after MG132 treatment. FLAG-CAS immunoprecipitates were immunoblotted to detect association of endogenous MDM2. Densitometric analysis of the abundance of immunoprecipitated MDM2 normalized to that of immunoprecipitated FLAG-CAS is shown (means ± SEM; n = 4 independent experiments). The immunoprecipitated MDM2 in BT474 cells without any treatments was set at 100% (*P < 0.05 by paired, two-tailed t test). (G) H1299 cells expressing empty vector, FLAG-CAS W127A , or FLAG-CAS WT were treated with MG132. Ubiquitylation of CAS was analyzed after immunoprecipitation. n = 2 independent experiments. (H) H1299 cells expressing MDM2 (WT, C/A mutant, or empty vector), FLAG-CAS (WT or F123A mutant), and GFP (transfection control) were immunoblotted for FLAG, MDM2, GFP, and actin. n = 3 independent experiments. (A) rBT474 cells transfected with scrambled or MDM2-specific siRNA were treated with lapatinib and subjected to annexin V staining. The percentage of annexin V-positive cells was analyzed by FACS. Results are mean percentages ± SEM and analyzed by paired, twotailed t test (*P < 0.05, n = 4 independent experiments). (B) rBT474 cells stably expressing control or MDM2-specific shRNA (#1 or #2) were injected into the mam-mary fat pad of female nude mice. The oral administration of lapatinib began when the average tumor volume surpassed 300mm 3 .Resultsaremean percentages ± SEM. The statistical difference in tumor volume was analyzed by one-way analysis of variance (ANOVA) (P < 0.001) followed by pairwise comparisons using the Bonferroni correction for multiple comparisons. *P < 0.05 between control and shMDM2 #1, and between control and shMDM2 #2 when the mice were treated with lapatinib. n values in the figure indicate the number of mice. (C) H1299 cells transfected with HA-HUWE1 (C/S) were treated with Nutlin-3a. HA-HUWE1 (C/S) immunoprecipitates were immunoblotted for MDM2 (left). Densitometric analysis of the abundance of immunoprecipitated MDM2 normalized to that of immunoprecipitated HA-HUWE1 (C/S) is shown (means ± SEM; n = 4 independent experiments). The amount of MDM2 that precipitated with HUWE1 in the absence of Nutlin-3a was set at 100% (*P <
